Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Paolo Troia-Cancio"'
Autor:
Sergio Serrano-Villar, Talia Sainz, Zhong-Min Ma, Netanya S Utay, Tae Wook-Chun, Surinder Mann, Angela D Kashuba, Basile Siewe, Anthony Albanese, Paolo Troia-Cancio, Elizabeth Sinclair, Anoma Somasunderam, Tammy Yotter, Steven G Deeks, Alan Landay, Richard B Pollard, Christopher J Miller, Santiago Moreno, David M Asmuth
Publikováno v:
PLoS Pathogens, Vol 13, Iss 5, p e1006368 (2017)
[This corrects the article DOI: 10.1371/journal.ppat.1005381.].
Externí odkaz:
https://doaj.org/article/b4a1aa6644d042a4b9efefd5e7c4b9ac
Autor:
Sergio Serrano-Villar, Talia Sainz, Zhong-Min Ma, Netanya S Utay, Tae-Wook Chun, Surinder Mann, Angela D Kashuba, Basile Siewe, Anthony Albanese, Paolo Troia-Cancio, Elizabeth Sinclair, Anoma Somasunderam, Tammy Yotter, Steven G Deeks, Alan Landay, Richard B Pollard, Christopher J Miller, Santiago Moreno, David M Asmuth
Publikováno v:
PLoS Pathogens, Vol 12, Iss 3, p e1005540 (2016)
Externí odkaz:
https://doaj.org/article/a6ef1c1428e54acb94946b04ab45ba3c
Autor:
Sergio Serrano-Villar, Talia Sainz, Zhong-Min Ma, Netanya S Utay, Tae-Wook Chun, Surinder Mann, Angela D Kashuba, Basile Siewe, Anthony Albanese, Paolo Troia-Cancio, Elizabeth Sinclair, Anoma Somasunderam, Tammy Yotter, Steven G Deeks, Alan Landay, Richard B Pollard, Christopher J Miller, Santiago Moreno, David M Asmuth
Publikováno v:
PLoS Pathogens, Vol 12, Iss 1, p e1005381 (2016)
Whether initiation of antiretroviral therapy (ART) regimens aimed at achieving greater concentrations within gut associated lymphoid tissue (GALT) impacts the level of mucosal immune reconstitution, inflammatory markers and the viral reservoir remain
Externí odkaz:
https://doaj.org/article/4c8ddb8fc36e4a4592983eaa38e14cda
Autor:
Angela D. M. Kashuba, Talia Sainz, Corbin G. Thompson, Alan L. Landay, Tae Wook Chun, David M. Asmuth, Juan Carlos Garcia, Christopher J. Miller, Surinder K Mann, Zhong-Min Ma, Sergio Serrano-Villar, Richard B. Pollard, Paolo Troia-Cancio, Netanya S. Utay
Publikováno v:
The Journal of infectious diseases, vol 216, iss 7
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Plasma, duodenal, and rectal tissue antiretroviral therapy (ART) drug concentrations, human immunodeficiency virus (HIV) RNA and HIV DNA copy numbers, and recovery of mucosal immunity were measured before and 9 months after initiation of 3 different
Autor:
Surinder K Mann, Elizabeth Sinclair, Richard B. Pollard, Steven G. Deeks, Christopher J. Miller, Anoma Somasunderam, Sergio Serrano-Villar, Alan L. Landay, Angela D. M. Kashuba, Zhong-Min Ma, Basile Siewe, Anthony Albanese, Talia Sainz, Tae Wook-Chun, Tammy Yotter, Netanya S. Utay, David M. Asmuth, Santiago Moreno, Paolo Troia-Cancio
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Serrano-Villar, S; Sainz, T; Ma, ZM; Utay, NS; Wook-Chun, T; Mann, S; et al.(2016). Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial. PLoS Pathogens, 12(1). doi: 10.1371/journal.ppat.1005381. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/9gn0z3z1
PLoS Pathogens, Vol 12, Iss 1, p e1005381 (2016)
PLoS pathogens, vol 12, iss 1
PLoS Pathogens
PLoS Pathogens, Vol 13, Iss 5, p e1006368 (2017)
Serrano-Villar, S; Sainz, T; Ma, Z-M; Utay, NS; Wook-Chun, T; Mann, S; et al.(2017). Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.. PLoS pathogens, 13(5), e1006368. doi: 10.1371/journal.ppat.1006368. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/1sc900c6
PLoS pathogens, vol 13, iss 5
PLoS pathogens, vol 12, iss 3
PLoS Pathogens, Vol 12, Iss 3, p e1005540 (2016)
Consejería de Sanidad de la Comunidad de Madrid
Serrano-Villar, S; Sainz, T; Ma, ZM; Utay, NS; Wook-Chun, T; Mann, S; et al.(2016). Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial. PLoS Pathogens, 12(1). doi: 10.1371/journal.ppat.1005381. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/9gn0z3z1
PLoS Pathogens, Vol 12, Iss 1, p e1005381 (2016)
PLoS pathogens, vol 12, iss 1
PLoS Pathogens
PLoS Pathogens, Vol 13, Iss 5, p e1006368 (2017)
Serrano-Villar, S; Sainz, T; Ma, Z-M; Utay, NS; Wook-Chun, T; Mann, S; et al.(2017). Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.. PLoS pathogens, 13(5), e1006368. doi: 10.1371/journal.ppat.1006368. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/1sc900c6
PLoS pathogens, vol 13, iss 5
PLoS pathogens, vol 12, iss 3
PLoS Pathogens, Vol 12, Iss 3, p e1005540 (2016)
Whether initiation of antiretroviral therapy (ART) regimens aimed at achieving greater concentrations within gut associated lymphoid tissue (GALT) impacts the level of mucosal immune reconstitution, inflammatory markers and the viral reservoir remain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d552062c27980ed880f69213cc4b32f6
https://hdl.handle.net/20.500.12530/41141
https://hdl.handle.net/20.500.12530/41141
Autor:
Ron M. Kagan, Robert W. Shafer, David Kaufman, Soo-Yon Rhee, George L. Melikian, William J. Towner, Dennis Israelski, Paolo Troia-Cancio, Andrew R. Zolopa, W. Jeffrey Fessel, Jonathan Taylor, Gregory K. Robbins
Publikováno v:
Melikian, George L; Rhee, Soo-Yon; Taylor, Jonathan; Fessel, W Jeffrey; Kaufman, David; Towner, William; et al.(2012). Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.. Antimicrobial agents and chemotherapy, 56(5), 2305-2313. UC Office of the President: California HIV/AIDS Research Program. Retrieved from: http://www.escholarship.org/uc/item/2j8581md
Determining the phenotypic impacts of reverse transcriptase (RT) mutations on individual nucleoside RT inhibitors (NRTIs) has remained a statistical challenge because clinical NRTI-resistant HIV-1 isolates usually contain multiple mutations, often in
Autor:
Paolo Troia-Cancio, Collin L. Ellis, Heather A. Overman, Richard B. Pollard, Thomas H. Knight, David M. Asmuth, Christopher J. Miller, Chin-Shang Li, Tammy Yotter, Zhong-Min Ma, Jian Wu, John C. Rutledge, Archana Maniar, Surinder K Mann, Anthony Albanese, Natalie J. Török, Timothy L. Hayes
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 57:363-370
Background The relationship between gut microbial community composition at the higher-taxonomic order level and local and systemic immunologic abnormalities in HIV disease may provide insight into how bacterial translocation impacts HIV disease. Meth
Publikováno v:
Surgical Infections. 14:322-324
Arcanobacterium haemolyticum can cause severe systemic infections and sepsis. Thus, accurate and timely identification of the organism is essential.Case report and review of the pertinent English-language literature.A 74-year-old male underwent repet
Autor:
Zhong-Min Ma, Timothy L. Hayes, David M. Asmuth, Richard B. Pollard, Paolo Troia-Cancio, Christopher J. Miller, Tammy Yotter, Anthony Albanese, Surinder K Mann, Thomas H. Knight, Gregory P. Melcher
Publikováno v:
AIDS (London, England). 26(13)
Objectives To examine immune restoration in duodenal tissue and correlates of reduction of immune activation in chronic HIV-infected patients randomized to different treatment regimens. Design Randomized clinical trial (RCT) comparing raltegravir to
Autor:
David M. Asmuth, Paolo Troia-Cancio
Publikováno v:
Expert review of anti-infective therapy. 9(6)
Evaluation of: Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359, 1429-1441 (2008). Maraviroc is the first commercially available HIV chemokine receptor antagonist targeti